This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nichi-Iko Pharmaceutical Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Shingo Iwamoto

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Shingo Iwamoto

less than a year

Mandato

Shingo Iwamoto serves as Representative Director & President at Nichi-Iko Pharmaceutical Co., Ltd. since 2023.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Shingo Iwamoto	Representative Director & President	less than a year	Nessun dato	Nessun dato
Shuji Ishida	Managing Executive Officer & Director	less than a year	Nessun dato	0% ¥ 0
Hiroshi Shimazaki	Senior Executive Officer & Head of Quality Assurance & Pharmacovigilance Division	no data	Nessun dato	Nessun dato
Takashi Kashiwagi	Senior Executive Officer & Head of Corporate Strategy & Planning Division	no data	Nessun dato	Nessun dato
Susumu Kanda	Managing Executive Officer & Director	less than a year	Nessun dato	Nessun dato
Hirotoshi Naruse	Managing Executive Officer & Director	less than a year	Nessun dato	0% ¥ 0
Atsushi Matsumoto	Senior Executive Officer	no data	Nessun dato	Nessun dato
Tadashi Kojima	Senior Executive Officer	no data	Nessun dato	Nessun dato
Toru Furukawa	Senior Executive Officer	no data	Nessun dato	Nessun dato
Osamu Mihara	Director & Senior Managing Executive Officer	less than a year	Nessun dato	0% ¥ 0
Atsushi Kosugi	Senior Executive Officer	no data	Nessun dato	Nessun dato
Peter Kaemmerer	Chief Executive Officer of Sagent Pharmaceuticals	no data	Nessun dato	Nessun dato

0.8yrs

Durata media

62yo

Età media

Gestione esperta: Il team dirigenziale di 4541 non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Shingo Iwamoto	Representative Director & President	less than a year	Nessun dato	Nessun dato
Shuji Ishida	Managing Executive Officer & Director	no data	Nessun dato	0% ¥ 0
Susumu Kanda	Managing Executive Officer & Director	less than a year	Nessun dato	Nessun dato
Hirotoshi Naruse	Managing Executive Officer & Director	no data	Nessun dato	0% ¥ 0
Osamu Mihara	Director & Senior Managing Executive Officer	no data	Nessun dato	0% ¥ 0
Kenji Akane	Executive VP & Director	14.1yrs	Nessun dato	0% ¥ 0

0.8yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 4541 non è considerato esperto (durata media del mandato 0.8 anni), il che suggerisce un nuovo consiglio.

This company listing is no longer active

Nichi-Iko Pharmaceutical Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

Less than half of directors are independent

Nichi-Iko Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

Recent updates

Third quarter 2023 earnings released: JP¥232 loss per share (vs JP¥15.76 loss in 3Q 2022)

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 14, 2023

Consensus forecasts updated

Less than half of directors are independent

Less than half of directors are independent

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 14, 2022

Consensus forecasts updated

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥59.63 loss per share (vs JP¥58.89 loss in 1Q 2022)

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 12, 2022

Sawai Group Holdings Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd. Announce Notice of Filing an Appeal in Patent Infringement Lawsuit Concerning Edirol Capsule

Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit Concerning Edirol Capsules Against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd

Price target decreased to JP¥700

Full year 2022 earnings: EPS and revenues miss analyst expectations

Now 21% undervalued after recent price drop

Nichi-Iko Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Nichi-Iko Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Nichi-Iko Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Tokyo District Court Renders Judgment on the Patent Infringement Lawsuit Concerning Edirol Capsules Against Sawai Pharmaceutical Co., Ltd., Nichi- Iko Pharmaceutical Co., Ltd. and Nissan Chemical Corporation

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to JP¥768

Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

Price target decreased to JP¥874

Second quarter 2022 earnings released: JP¥164 loss per share (vs JP¥2.25 loss in 2Q 2021)

Upcoming dividend of JP¥10.00 per share

Nichi-Iko Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Second Quarter and Fiscal Year Ending March 31, 2022

Nichi-Iko Pharmaceutical Co., Ltd. announced that it has received ¥5.23102 billion in funding from MediPal Holdings Corporation

Nichi-Iko Pharmaceutical Co., Ltd. announced that it expects to receive ¥5.23102 billion in funding from MediPal Holdings Corporation

Fuji Chemical Industries Co., Ltd. agreed to acquire Toyama No. 2 Factory of Nichi-Iko in Namerikawa City, Toyama Prefecture from Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541).

Full year 2021 earnings released: JP¥65.27 loss per share (vs JP¥80.41 profit in FY 2020)

Price target decreased to JP¥962

Full year 2021 earnings released: JP¥65.27 loss per share (vs JP¥80.41 profit in FY 2020)

Mitani Sangyo Co., Ltd. (TSE:8285) agreed to acquire remaining 49% stake in Active Pharma Co., Ltd. from Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541).

Upcoming dividend of JP¥15.00 per share

New 90-day high: JP¥1,106

Chugai Pharmaceutical Co., Ltd. Refiles Patent Infringement Lawsuit Concerning Edirol Capsules

Third quarter 2021 earnings released: JP¥5.65 loss per share (vs JP¥39.40 profit in 3Q 2020)

Revenue and earnings miss expectations

Nichi-Iko Pharmaceutical Co., Ltd. (TSE:4541) acquired Generics and Takayama Plane related Businesses from Teva Takeda Pharma Ltd.

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 10, 2021

New 90-day low: JP¥994

New 90-day low: JP¥997

Chugai Pharmaceutical Co., Ltd. Files Patent Infringement Lawsuit Against Nissan Chemical Corporation, Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd

Nichi-Iko Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Nov 11, 2020

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media